Jane Street Group LLC Has $857,000 Stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Jane Street Group LLC grew its holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 328.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 64,323 shares of the company’s stock after buying an additional 49,317 shares during the period. Jane Street Group LLC owned 0.25% of Eton Pharmaceuticals worth $857,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Schonfeld Strategic Advisors LLC lifted its position in shares of Eton Pharmaceuticals by 421.3% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 89,664 shares of the company’s stock valued at $1,194,000 after buying an additional 72,464 shares during the last quarter. Nantahala Capital Management LLC lifted its position in shares of Eton Pharmaceuticals by 12.0% in the fourth quarter. Nantahala Capital Management LLC now owns 1,118,483 shares of the company’s stock valued at $14,898,000 after buying an additional 119,750 shares during the last quarter. Northern Trust Corp lifted its position in shares of Eton Pharmaceuticals by 35.6% in the fourth quarter. Northern Trust Corp now owns 86,957 shares of the company’s stock valued at $1,158,000 after buying an additional 22,827 shares during the last quarter. Tower Research Capital LLC TRC acquired a new stake in shares of Eton Pharmaceuticals in the fourth quarter valued at approximately $86,000. Finally, Marshall Wace LLP lifted its position in shares of Eton Pharmaceuticals by 75.3% in the fourth quarter. Marshall Wace LLP now owns 36,182 shares of the company’s stock valued at $482,000 after buying an additional 15,545 shares during the last quarter. 27.86% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ETON. HC Wainwright reaffirmed a “buy” rating and issued a $33.00 price objective on shares of Eton Pharmaceuticals in a research report on Wednesday, March 19th. B. Riley reaffirmed a “buy” rating and issued a $26.00 price objective (up from $24.00) on shares of Eton Pharmaceuticals in a research report on Friday, May 16th. Finally, Craig Hallum raised their price objective on Eton Pharmaceuticals from $26.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday, May 14th.

Eton Pharmaceuticals Trading Down 2.2%

Shares of NASDAQ ETON opened at $19.81 on Friday. The firm has a market cap of $531.26 million, a P/E ratio of -90.05 and a beta of 1.22. Eton Pharmaceuticals, Inc. has a 1-year low of $3.18 and a 1-year high of $21.48. The business’s 50 day moving average is $15.31 and its 200-day moving average is $14.28.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its earnings results on Tuesday, May 13th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.02). The firm had revenue of $17.28 million for the quarter, compared to the consensus estimate of $14.33 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. Analysts forecast that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current year.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.